Atossa Therapeutics, Inc. SEC filings ATOS
Atossa Therapeutics, Inc. has 641 filings in SEC EDGAR's recent list, going back to Mar 30, 2010. Its latest annual report, Form ARS, was filed on Mar 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 7, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 9, 2026 (material agreement, change to shareholder rights, other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | May 23, 2024 | — |
| CORRESP | Letter to the SEC | May 21, 2024 | — |
| UPLOAD | Letter from the SEC | May 21, 2024 | — |
| DEL AM | Filing | May 14, 2024 | — |
| EFFECT | Filing | Apr 29, 2021 | — |
| CORRESP | Letter to the SEC | Apr 27, 2021 | — |
| UPLOAD | Letter from the SEC | Apr 26, 2021 | — |
| EFFECT | Filing | Jan 29, 2021 | — |
| CORRESP | Letter to the SEC | Jan 28, 2021 | — |
| UPLOAD | Letter from the SEC | Jan 28, 2021 | — |
| EFFECT | Filing | Dec 8, 2020 | — |
| CORRESP | Letter to the SEC | Dec 7, 2020 | — |
| CORRESP | Letter to the SEC | Dec 7, 2020 | — |
| UPLOAD | Letter from the SEC | Nov 27, 2020 | — |
| EFFECT | Filing | Sep 10, 2020 | — |
| UPLOAD | Letter from the SEC | Sep 8, 2020 | — |
| CORRESP | Letter to the SEC | Sep 8, 2020 | — |
| EFFECT | Filing | Jun 14, 2018 | — |
| UPLOAD | Letter from the SEC | Jun 12, 2018 | — |
| CORRESP | Letter to the SEC | Jun 12, 2018 | — |
| EFFECT | Filing | May 9, 2018 | — |
| CORRESP | Letter to the SEC | May 7, 2018 | — |
| CORRESP | Letter to the SEC | May 7, 2018 | — |
| CORRESP | Letter to the SEC | May 3, 2018 | — |
| UPLOAD | Letter from the SEC | Apr 25, 2018 | — |
| CORRESP | Letter to the SEC | Apr 23, 2018 | — |
| UPLOAD | Letter from the SEC | Apr 6, 2018 | — |
| EFFECT | Filing | Oct 5, 2017 | — |
| CORRESP | Letter to the SEC | Oct 3, 2017 | — |
| UPLOAD | Letter from the SEC | Oct 3, 2017 | — |
| EFFECT | Filing | Mar 28, 2017 | — |
| CORRESP | Letter to the SEC | Mar 28, 2017 | — |
| CORRESP | Letter to the SEC | Mar 28, 2017 | — |
| CORRESP | Letter to the SEC | Mar 23, 2017 | — |
| CORRESP | Letter to the SEC | Mar 22, 2017 | — |
| EFFECT | Filing | Jun 15, 2016 | — |
| CORRESP | Letter to the SEC | Jun 13, 2016 | — |
| UPLOAD | Letter from the SEC | Jun 10, 2016 | — |
| EFFECT | Filing | Dec 16, 2015 | — |
| CORRESP | Letter to the SEC | Dec 14, 2015 | — |
| UPLOAD | Letter from the SEC | Dec 9, 2015 | — |
| EFFECT | Filing | Jul 8, 2015 | — |
| UPLOAD | Letter from the SEC | Jul 6, 2015 | — |
| CORRESP | Letter to the SEC | Jul 6, 2015 | — |
| EFFECT | Filing | May 8, 2015 | — |
| 8-A12B | Filing | May 22, 2014 | — |
| EFFECT | Filing | Apr 25, 2014 | — |
| EFFECT | Filing | Apr 21, 2014 | — |
| EFFECT | Filing | Dec 13, 2013 | — |
| CORRESP | Letter to the SEC | Dec 12, 2013 | — |
| CORRESP | Letter to the SEC | Dec 11, 2013 | — |
| UPLOAD | Letter from the SEC | Dec 9, 2013 | — |
| EFFECT | Filing | Nov 29, 2013 | — |
| EFFECT | Filing | Apr 23, 2013 | — |
| CORRESP | Letter to the SEC | Apr 22, 2013 | — |
| EFFECT | Filing | Apr 16, 2013 | — |
| D | Filing | Apr 11, 2013 | — |
| UPLOAD | Letter from the SEC | Feb 21, 2013 | — |
| CORRESP | Letter to the SEC | Feb 5, 2013 | — |
| UPLOAD | Letter from the SEC | Jan 30, 2013 | — |
| CT ORDER | Filing | Nov 14, 2012 | — |
| CERTNAS | Auto-generated paper document | Nov 7, 2012 | — |
| EFFECT | Filing | Nov 7, 2012 | — |
| CORRESP | Letter to the SEC | Nov 5, 2012 | — |
| CORRESP | Letter to the SEC | Nov 5, 2012 | — |
| CORRESP | Letter to the SEC | Oct 26, 2012 | — |
| CORRESP | Letter to the SEC | Oct 26, 2012 | — |
| CORRESP | Letter to the SEC | Oct 19, 2012 | — |
| UPLOAD | Letter from the SEC | Oct 16, 2012 | — |
| CORRESP | Letter to the SEC | Oct 3, 2012 | — |
| CORRESP | Letter to the SEC | Sep 12, 2012 | — |
| CORRESP | Letter to the SEC | Sep 12, 2012 | — |
| CORRESP | Letter to the SEC | Sep 10, 2012 | — |
| CORRESP | Letter to the SEC | Sep 7, 2012 | — |
| CORRESP | Letter to the SEC | Aug 13, 2012 | — |
| 8-A12B | Form 8-a12b | Jul 24, 2012 | — |
| CORRESP | Letter to the SEC | Jul 24, 2012 | — |
| CORRESP | Letter to the SEC | Jul 20, 2012 | — |
| CORRESP | Letter to the SEC | Jun 25, 2012 | — |
| UPLOAD | Letter from the SEC | Jun 19, 2012 | — |
| CORRESP | Letter to the SEC | Jun 18, 2012 | — |
| UPLOAD | Letter from the SEC | Jun 13, 2012 | — |
| CORRESP | Letter to the SEC | Jun 11, 2012 | — |
| UPLOAD | Letter from the SEC | Jun 6, 2012 | — |
| UPLOAD | Letter from the SEC | Apr 20, 2012 | — |
| UPLOAD | Letter from the SEC | Mar 12, 2012 | — |
| D/A | Filing | Jun 24, 2011 | — |
| D | Filing | May 13, 2011 | — |
| RW | Filing | Feb 15, 2011 | — |
| D/A | Filing | Sep 28, 2010 | — |
| RW | Filing | Jul 28, 2010 | — |
| D | Filing | Jun 24, 2010 | — |
Showing 92 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ATOS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Seattle, WA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1488039
- Former names
- ATOSSA GENETICS INC (until Nov 13, 2019)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.